• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Anesthesiology >Comparison of palonosetron, granisetron, and ramosetron for the prevention of postoperative nausea and vomiting after laparoscopic gynecologic surgery: a prospective randomized trial
【24h】

Comparison of palonosetron, granisetron, and ramosetron for the prevention of postoperative nausea and vomiting after laparoscopic gynecologic surgery: a prospective randomized trial

机译：帕洛诺司琼，格拉司琼和雷莫司琼预防腹腔镜妇科手术后恶心和呕吐的比较：一项前瞻性随机试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are reported to have potent antiemetic effects for postoperative nausea and vomiting (PONV). The purpose of this study was to prospectively evaluate the efficacy of palonosetron, granisetron, and ramosetron for the prevention of PONV in patients undergoing laparoscopic gynecologic surgery. Methods In this prospective, randomized observational study, 105 healthy female patients who were undergoing laparocopic hystectomy under general anaesthesia were enrolled (clinical trial number: NCT01752374, www.clinicaltrials.gov ). Patients were divided into three groups: the palonostron (0.075?mg i.v.; n?=?35), the granisetron group (3?mg i.v.; n?=?35), and the ramosetron group (0.3?mg i.v.; n?=?35). The treatments were given before the end of surgery. The incidence of PONV, severity of nausea/vomiting, and the use of rescue antiemetic requirements during the first 48?h after surgery were evaluated. Results The overall incidence of PONV was 33.3?% for this series. The number of complete responders at 48?h after the surgery was 21 (60.0?%) for palonosetron, 24 (68.6?%) for granisetron, and 26 (71.4?%) for ramosetron, representing no statistical difference (P?=?0.086). Conclusions There were no significant differences in the overall incidence of postoperative nausea and vomiting and complete responders for palonosetron, granisetron and ramosetron group. Trial registration Clinical trial number: NCT01752374 , www.clinicaltrials.gov .
机译：背景技术据报道，选择性3型5-羟色胺（5-HT3）受体拮抗剂对术后恶心和呕吐（PONV）具有有效的止吐作用。这项研究的目的是前瞻性评估帕洛诺司琼，格拉司琼和雷莫司琼在接受腹腔镜妇科手术的患者中预防PONV的功效。方法在这项前瞻性，随机观察性研究中，纳入了105名在全身麻醉下接受腹腔镜子宫切除术的健康女性患者（临床试验编号：NCT01752374，www.clinicaltrials.gov）。患者分为三组：帕洛司琼（0.075 mg iv;n≥35），格拉司琼组（3 mg iv;n≥35）和雷莫司琼组（0.3 mg iv;n≥35）。 =？35）。治疗是在手术结束前进行的。在手术后的最初48小时内，评估PONV的发生率，恶心/呕吐的严重程度以及使用止吐药的要求。结果该系列的PONV总发生率为33.3％。术后48小时的完全反应者中，帕洛诺司琼为21（60.0％），格兰尼司琼为24（68.6％），雷莫司琼为26（71.4％），无统计学差异（P = 2。 0.086）。结论帕洛诺司琼，格拉司琼和雷莫司琼组的术后恶心和呕吐及完全缓解反应的总发生率无显着差异。试验注册临床试验编号：NCT01752374，www.clinicaltrials.gov。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号